대한뉴팜

054670KOSDAQ의약품 제조업

59.8 / 100

Reference Date: 2026-07-24

Financial Score23.5 / 40

News Sentiment21.3 / 25

Momentum5.0 / 20

Disclosure10.0 / 15

AI Analysis: PER is significantly undervalued vs. peers but the high debt ratio poses financial risk. Slightly up 1.3% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

DaeHan New Pharm operates in various sectors including specialty pharmaceuticals, non-essential pharmaceuticals (obesity & wellness injectables), and animal pharmaceuticals, focusing on chronic disease treatments and expanding into new areas such as dementia and Parkinson's. The company is diversifying its business through animal pharmaceuticals and biotech, leveraging stem cell-based anti-aging and cell therapies. Sales are structured as a multi-product, small-volume model, and the company manages foreign exchange risks through asset-liability matching strategies.

Number of Employees

393people

Average Salary

62.3M KRW

Score Calculation Basis

Detailed Financial Score

PER

5.04Industry Average 11.238.0Point

Half of industry avg (excellent)

PBR

0.56Industry Average 0.815.5Point

Lower than industry avg (good)

ROE

11.50Industry Average 4.017.0Point

2.9x industry avg (excellent)

Debt Ratio

41.35Industry Average 12.430.0Point

3.3x industry avg (risky)

Trend 2023~20253.0 / 10 points

Revenue Growth Rate

0.5 / 3

Avg ▼0.4% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼19.0% (2-year basis)

ROE Trend

2.5 / 4

Avg ROE 12.2% (declining, 3yr)

Detailed News Sentiment

1 totalPositive 1Neutral 0Negative 0Average Sentiment Score 85

Positive
대한뉴팜, '반려동물용' 장기지속형 항생제 출시
대한뉴팜의 새로운 장기지속형 반려동물 항생제 출시로 인해 시장 경쟁력 강화 및 보호자 편의 증대 기대.

Detailed Momentum

52-week position1.0Point

Near 52w low (16%, downtrend)

Current 5,480Won52-week high 7,51052-week low 5,090

1-month return3.0Point

1m 1.29% (flat)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0

Neutral공정거래자율준수프로그램운영현황2026-07-15
Neutral[기재정정]사업보고서 (2025.12)2026-07-07
Neutral[기재정정]감사보고서제출2026-07-07